EMERGENT BIOSOLUTIONS INC (EBS)       12.3  +0.53 (+4.5%)

12.3  +0.53 (+4.5%)

US29089Q1058 - Common Stock - After market: 12.32 +0.02 (+0.16%)


Fundamental Rating

5

Taking everything into account, EBS scores 5 out of 10 in our fundamental rating. EBS was compared to 631 industry peers in the Biotechnology industry. EBS has a medium financial health rating, its profitability is only medium as well. A decent growth rate in combination with a cheap valuation! Better keep an eye on EBS.




Profitability

Profitability Rating

6

EBS's Return On Assets of 1.84% is amongst the best returns of the industry. EBS outperforms 93% of its industry peers. The industry average Return On Assets is -44.83%.
EBS has a Profit Margin of 3.54%. This is amongst the best returns in the industry. The industry average is -464.10%. EBS outperforms 87% of its industry peers.

EBS has a Piotroski-F score of 5.00. This indicates an average health and profitability for EBS.
EBS has a Return On Equity of 3.69%. This is below the industry average of 22.42%. 88% of the industry peers outperform EBS.
VS Industry

ROA (1.84%) VS Industry: 93% outperformed.

-950.38
52.28

ROE (3.69%) VS Industry: 12% outperformed.

0.21
217.75

Profit Margin (3.54%) VS Industry: 87% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

8

With a Price/Earnings Ratio of 4.82, the valuation of EBS can be described as very cheap.
Compared to an average industry Price/Earning Ratio of 14.69, EBS is valued a bit cheaper than its industry peers.
The Forward Price/Earnings Ratio of 6.55 indicates a rather cheap valuation of EBS.
EBS's low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

When comparing the current price to the book value of EBS, it is valued rather cheaply. It is trading at 0.42 times its book value.
Compared to an average industry price book ratio of 1.71, EBS is valued rather cheaply. On top of this, EBS is cheaper than 88% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of EBS to the average industry ratio of 1.07, EBS is valued more expensive than its industry peers. 87% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (4.82) VS Industry: 79% outperformed.

441.89
0.13

Price/Book (0.42) VS Industry: 88% outperformed.

127.24
0.10

Enterprise Value/ EBITDA (4.02) VS Industry: 13% outperformed.

3,469.94
0.01

Growth

Growth Rating

4

Measured over the past 5 years, EBS shows a very strong growth in Earnings Per Share. The EPS has been growing by 35.78% on average per year.
EBS is expected to show a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 23.49% yearly.
The Revenue has been growing by 29.68% on average over the past 5 years. This is a very strong growth!
The Revenue has decreased by -8.42% in the past year.

The Revenue is expected to decrease by -6.60% on average over the next 5 years.
The earnings per share for EBS have decreased strongly by -50.68% in the last year.
The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS35.78% 36.87% -50.68% -100.91% -44.07% -22.57% 23.49%
Revenue29.68% 31.83% -8.42% -31.96% -16.33% -10.83% -6.6%

Health

Health Rating

4

EBS has a Current Ratio of 4.17. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
EBS has a Quick Ratio of 2.13. This indicates that EBS is financially healthy and has no problem in meeting its short term obligations.
EBS is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of -0.81.
EBS has a Piotroski-F score of 5.00. This indicates an average health and profitability for EBS.

Compared to an average industry Current Ratio of 6.16, EBS is worse placed to pay its short term obligations than its industry peers.
When comparing the Quick Ratio of EBS to the average industry Current Ratio of 6.05, EBS is less able to pay its short term obligations than its industry peers. 82% of its industry peers have a better Quick Ratio.
EBS has one of the worst Debt to Equity ratios in its industry. 92% of its industry peers require less debt for financing their operations.
EBS has an Altman-Z score of 1.75. This is a bad value and indicates that EBS is not financially healthy and even has some risk of bankruptcy.
VS Industry

Debt/Equity (0.71) VS Industry: 8% outperformed.

15.37
0.00

Quick Ratio (2.13) VS Industry: 18% outperformed.

0.02
84.53

Current Ratio (4.17) VS Industry: 36% outperformed.

0.02
85.09

Altman-Z (1.75) VS Industry: 65% outperformed.

-135.10
443.02

Dividend

Dividend Rating

0

No dividends for EBS!.

EBS Daily chart

EMERGENT BIOSOLUTIONS INC12.3

NYSE:EBS (11/30/2022, 7:04:00 PM)+0.53 (+4.5%)

After market: 12.32 +0.02 (+0.16%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 01-09 2023-01-09
Ins Owners 4% Inst Owners 81.92%
Market Cap 613.62M Analysts 74.55
Valuation
PE 4.82 Fwd PE 6.55
PEG (NY) N/A PEG (5Y) 0.13
P/S 0.41 P/B 0.42
EV/EBITDA 4.02
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -50.68% EPS 3Y 36.87%
EPS 5Y 35.78% EPS growth Q2Q -252.78%
EPS Next Y -100.91% EPS Next 2Y -44.07%
EPS Next 3Y -22.57% EPS Next 5Y 23.49%
Revenue growth 1Y -8.42% Revenue growth 3Y 31.83%
Revenue growth 5Y 29.68% Revenue growth Q2Q -27.05%
Revenue Next Year -31.96% Revenue Next 2Y -16.33%
Revenue Next 3Y -10.83% Revenue Next 5Y -6.6%
Health
Current Ratio 4.17 Quick Ratio 2.13
Altman-Z 1.75 F-Score 5
Debt/Equity 0.71 WACC 7.74%
ROIC/WACC 1.4
Profitability
ROA 1.84% ROE 3.69%
ROICexgc 10.81% ROIC 5.94%
PM 3.54% OM 13.98%
Asset Turnover 0.52

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA